Aleksander A Mathé

Prof. Dr. Aleksander A Mathé


Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Frontiers in Behavioral Neuroscience
Verified
Journal Article
Open access
GWGang Wu
Gang Wu
AFAdriana Feder
Adriana Feder
HCHagit Cohen
Hagit Cohen
JKJoanna J. Kim
Joanna J. Kim
SCSolara Calderon
Solara Calderon
AMAleksander A Mathé
Aleksander A Mathé
Resilience is the ability to adapt successfully in the face of stress and adversity. Stressful life events, trauma, and chronic adversity can have a substantial impact on brain function and structure, and can result in the development of posttraumatic stress disorder (PTSD), depression and other psychiatric disorders. However, most individuals do not develop such illnesses after experiencing stressful life events, and are thus thought to be resilient. Resilience as successful adaptation relies on effective responses to environmental challenges and ultimate resistance to the deleterious effects of stress, therefore a greater understanding of the factors that promote such effects is of great relevance. This review focuses on recent findings regarding genetic, epigenetic, developmental, psychosocial, and neurochemical factors that are considered essential contributors to the development of resilience. Neural circuits and pathways involved in mediating resilience are also discussed. The growing understanding of resilience factors will hopefully lead to the development of new pharmacological and psychological interventions for enhancing resilience and mitigating the untoward consequences.

5 October 2011 in Neuropsychopharmacology
Verified
Journal Article
Closed access
HCHagit Cohen
Hagit Cohen
TLTianmin Liu
Tianmin Liu
NKNitsan Kozlovsky
Nitsan Kozlovsky
ZKZeev Kaplan
Zeev Kaplan
JZJoseph Zohar
Joseph Zohar
AMAleksander A Mathé
Aleksander A Mathé

24 January 2015 in International Journal of Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
YWY. B. Wei
Y. B. Wei
LBLena Backlund
Lena Backlund
GWGregers Wegener
Gregers Wegener
AMAleksander A Mathé
Aleksander A Mathé
CLCatharina Lavebratt
Catharina Lavebratt
Telomeres are protective DNA-protein complexes at the ends of each chromosome, maintained primarily by the enzyme telomerase. Shortening of the blood leukocyte telomeres is associated with aging, several chronic diseases, and stress, eg, major depression. Hippocampus is pivotal in the regulation of cognition and mood and the main brain region of telomerase activity. Whether there is telomere dysfunction in the hippocampus of depressed subjects is unknown. Lithium, used in the treatment and relapse prevention of mood disorders, was found to protect against leukocyte telomere shortening in humans, but the mechanism has not been elucidated. To answer the questions whether telomeres are shortened and the telomerase activity changed in the hippocampus and whether lithium could reverse the process, we used a genetic model of depression, the Flinders Sensitive Line rat, and treated the animals with lithium. Telomere length, telomerase reverse transcriptase (Tert) expression, telomerase activity, and putative mediators of telomerase activity were investigated in the hippocampus of these animals. The naïve Flinders Sensitive Line had shorter telomere length, downregulated Tert expression, reduced brain-derived neurotrophic factor levels, and reduced telomerase activity compared with the Flinders Resistant Line controls. Lithium treatment normalized the Tert expression and telomerase activity in the Flinders Sensitive Line and upregulated β-catenin. This is the first report showing telomere dysregulation in hippocampus of a well-defined depression model and restorative effects of lithium treatment. If replicated in other models of mood disorder, the findings will contribute to understanding both the telomere function and the mechanism of lithium action in hippocampus of depressed patients.

22 September 2014 in Neuropsychopharmacology
Verified
Journal Article
Closed access
SCShlomi Cohen
Shlomi Cohen
EVElla Vainer
Ella Vainer
MMMichael A Matar
Michael A Matar
NKNitsan Kozlovsky
Nitsan Kozlovsky
ZKZeev Kaplan
Zeev Kaplan
HCHagit Cohen
Hagit Cohen

3 October 2020 in International Journal of Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
AMAleksander A Mathé
Aleksander A Mathé
MMMiranda Michaneck
Miranda Michaneck
EBElisabeth Berg
Elisabeth Berg
DCDennis S Charney
Dennis S Charney
JMJames W Murrough
James W Murrough
Since about one-third of patients with major depressive disorder (MDD) do not respond adequately to available antidepressants, there is a need for treatments based on novel mechanisms of action. Neuropeptide Y (NPY), a normal brain constituent, is reduced in cerebrospinal fluid of patients with MDD and post-traumatic stress disorder and in corresponding rodent models. Moreover, NPY administered centrally or intranasally rescues pathophysiology in these models. Consequently, we conducted the first, to our knowledge, controlled trial of NPY as a treatment for MDD. Thirty MDD patients on a stable dose of a conventional antidepressant insufflated 6.8 mg NPY (n = 12) or placebo (n = 18) in a double blind randomized fashion. Effects were assessed at baseline, +1 hour, +5 hours, +24 hours, and +48 hours. The primary outcome was change in depression severity measured with the Montgomery-Åsberg Depression Rating Scale (MADRS). NPY was superior to placebo at +24 hours (change −10.3 [95% CI: −13.8; −6.8]) vs −5.6 (95% CI: −8.4; −2.7); group*time F = 3.26, DF = (1,28), P = .04; Cohen’s d = 0.67). At +5 hours MADRS decreased −7.1 ([95% CI: −10.0; −4.2] vs −3.5 [95% CI: −5.8; −1.2]; group*time F = 2.69, DF = (1,28), P = .05; Cohen’s d = 0.61). MADRS reduction at +48 hours was not significant. Since no results regarding the trajectory of NPY effects existed prior to this study we extrapolated from the known NPY biology and predicted the effects will occur 5–48 hours post insufflation. We chose +48 hours as the primary endpoint and +1, +5, and +24 hours as secondary endpoints. The results, the first of their kind, indicate that insufflated NPY is antidepressant, despite not meeting the primary outcome, and call for dose ranging and repeated NPY insufflation trials. EudraCT Number: 2014-000129-19.

1 September 2007 in Physiology & Behavior
Verified
Journal Article
Closed access
AMAleksander A Mathé
Aleksander A Mathé
HHHenriette Husum
Henriette Husum
AKAram El Khoury
Aram El Khoury
PJPatricia Jiménez-Vasquez
Patricia Jiménez-Vasquez
SGSusanne H.M. Gruber
Susanne H.M. Gruber
FAFrancesco Angelucci
Francesco Angelucci